Drug Target Review

NOVEMBER 6, 2023

Advances in disease understanding and combination strategies in haematology We now know that blood cancers are characterised by molecular and phenotypic heterogeneity. These regimens frequently include one or two small molecule inhibitors and immuno-oncology (IO) therapies, such as monoclonal antibodies and T-cell engagers.

Small Molecule 111

Small Molecule Therapies Treatment Immune Response 111

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Codon

JUNE 11, 2024

Biologists use nanopores for everything from diagnosing diseases and monitoring changes within rainforest ecosystems to discovering proteins from microbes frozen in Icelandic glaciers. A scientist can isolate DNA and load up a flow cell in fifteen minutes. Nanopore devices work incredibly fast. An Oxford Nanopore device.

DNA 73

DNA Engineering RNA Small Molecule 73

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Agency IQ

APRIL 19, 2024

FDA advisors endorse minimal residual disease (MRD) as accelerated approval endpoint for multiple myeloma Last week, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of using minimal residual disease (MRD) as an accelerated approval endpoint for multiple myeloma.

FDA 40

FDA Disease Trials Clinical Trials 40

Codon

MARCH 19, 2024

Most people die from cardiovascular disease, while others succumb to Alzheimer’s and cancer. Take cardiovascular disease as an example. However, this approach is imperfect because it only addresses one manifestation of the disease, rather than its root. José Luis Ricón ( Nintil ) writes about aging for Issue 01.

DNA 56

DNA Small Molecule Regulations Laboratories 56